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Introduction  
Recent advances in intracellular protein delivery have enabled more in-depth analyses of
cellular functions. A specialized family of SNARE proteases, known as Botulinum
Neurotoxins, blocks neurotransmitter exocytosis, which leads to systemic toxicity caused by
flaccid paralysis. These pharmaceutically valuable enzymes have also been helpful in the
study of SNARE functions. As can be seen in Figure 1A, SNARE bundle formation causes
vesicle docking at the presynapse. Although these toxins are systemically toxic, no known
cytotoxic effects have been reported with the curious exception of the Botulinum serotype C 
[1]. This enzyme cleaves intracellular SNAP25, as does serotype A and E, but also,
exceptionally, cleaves Syntaxin 1. Using an array of lipid and polymer transfection reagents
we were able to deliver different combinations of Botulinum holoenzymes into the normally
unaffected, Neuro2A, SH-SY5Y, PC12, and Min6 cells to analyze the individual
contribution of each SNARE protein and their cleaved peptide products.  
Results and Discussion 
Transfection reagents were able to abundantly and rapidly transduce SNARE proteases and
peptides into cells [2]. Figure 1B shows the serotype C protease delivered into Neuro2A cells
where it can cleave intracellular Syntaxin 1 and SNAP25 while Figure 1C shows the type D 
protease able to cleave synatobrevin. Using cell survival assays we also determined that the
serotype C as well as the combination of type C and D caused profound cytotoxicity in the
above-mentioned non-neuronal cell types that expands upon the observations seen on
neuronal cells [1]. We observed that both apoptosis and necrosis mechanisms could be at
play due to the appearance of morphonuclear abnormalities and increased propidium iodide
staining respectively. Our results show that the freely released syntaxin and syntaxin plus

Fig. 1. (a) Schematic SNARE bundle formation. Western immunoblotting of syntaxin,
SNAP25, and synaptobrevin for the type C protease; (b) and type D protease; (c) delivered
with an array of transfection reagent.  
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synaptobrevin peptides products, now 
separated from their transmembrane
anchors and still able to form SNARE
complexes (determined by GST-pull
down experiments), could wreak 
havoc on the intracellular trafficking
machinery. This mechanism was 
confirmed by the direct cellular
penetration of the SNARE peptide
fragments potentiated by the very
same transfection reagents, Lipo-
fectamine LTX. As can be seen in
Figure 2A, SNARE peptides,
mimicking the intracellular protease
products, cause cytotoxic effects
mirroring the loss of viability seen
with the proteases. The viability of
Neuro2A cells was strongly reduced
in the presence of syntaxin as well as
syntaxin plus synaptobrevin. The
addition of all three SNARE subunits
might partially rescue this cytotoxicity
mechanism as they could stoichio-
metrically compete with each other
preventing them from binding onto
SNARE domains crucial for proper
intracellular trafficking (Figure 2A
last column). Figure 2B shows
Neuro2A cells treated with the 45 aa fluorescent (FITC) syntaxin fragment while Figure 2C
shows the same amount of FITC-syntaxin added in the presence of Lipofectamine LTX. A 
clear elevation of cell penetration can be observed. The freely diffusible syntaxin fragments, 
shown to cause cytotoxic effects in these tested cell types, were also shown to inhibit neurite
outgrowth in differentiated PC12 cells. The treatment of ex vivo cortical cells with the
holoenzymes and SNARE peptides showed a parallel cytotoxic effect and an observable
Wallerian degeneration. Here we show for the first time that the type C's cytotoxic effect can
also be observed in non-neuronal cells. Following our investigation we determine that the
free floating, unanchored, syntaxin fragment is the exacerbating cytotoxic factor. Since
syntaxin peptide fragments, compounded by synaptobrevin peptide fragments, cause
cytotoxicity, we propose that the subsequent formation of erroneous SNARE complexes
would have disastrous effects upon cell viability. These results open the door for a dual-
acting pharmacological intervention that could simultaneously inhibit secretion while also
destroying tumors cells. Our results thus open the door for translational trials of SNARE
proteases and SNARE peptides as anti-neoplastic agents. This concomitant inhibition of
exocytosis and cytotoxicity could also yield benefits for the targeted treatment of
neuroendocrine disorders [3]. 
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Fig. 2. (a) Cell survival assay of Neuro2A cells
treated with SNARE peptide fragments. Neuro2A
cells with FITC-syntaxin (45 aa) in the absence (b)
or presence (c) of Lipofectamine LTX. 
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